Buy & Sell Amgen, Inc. (AMGN) – Amgen, Inc. Price Today
Aura AI Summary
Key Stats
- $182.21BMarket Cap
- HealthSector
- -8.93%3M Drawdown
- $227.49BEnterprise Value
- 2.99%Dividend Yield
- 75 daysTypical Hold Time
Amgen, Inc. (AMGN) is currently valued at a market capitalization of $182.21B, with an enterprise value of $227.49B. Over the past 52 weeks, Amgen, Inc. has traded between a low of $271.18 and a high of $388.16, highlighting its annual price range. Over the past three months, Amgen, Inc. has recorded a drawdown of -8.93%, reflecting recent price volatility. Amgen, Inc. offers a dividend yield of 2.99%, with the most recent dividend of $2.52 paid on 15 May 26. On average, investors hold Amgen, Inc. for approximately 75 days, indicating typical investor behavior on the platform.
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Most Recent News
US forces Anthropic to take down AI models over national security concerns, sparking debate on AI policy.
The US government ordered Anthropic to take its two latest AI models, Fable 5 and Mythos 5, offline citing unspecified national security concerns. This move followed reports that Amazon researchers found ways to bypass the AI's safety measures, promp...
Microsoft remains a strong long-term buy with 15% EPS growth and AI-driven cloud expansion despite risks.
Microsoft continues to be a core long-term investment, offering a solid 15% earnings per share (EPS) growth at a reasonable 22 times forward valuation after a recent price pullback. The company is aggressively investing in artificial intelligence, en...
Amazon seen as a buy despite short-term cash flow drop due to strong AI-driven growth in AWS.
Amazon's free cash flow has sharply declined to $1.2 billion from $25.9 billion due to increased capital expenditures driven by aggressive AI investments. However, AWS revenue grew 28% in Q1 2026 with expanding margins, supported by custom silicon te...